JP2018526028A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526028A5
JP2018526028A5 JP2018530657A JP2018530657A JP2018526028A5 JP 2018526028 A5 JP2018526028 A5 JP 2018526028A5 JP 2018530657 A JP2018530657 A JP 2018530657A JP 2018530657 A JP2018530657 A JP 2018530657A JP 2018526028 A5 JP2018526028 A5 JP 2018526028A5
Authority
JP
Japan
Prior art keywords
item
seq
car
isolated
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018530657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526028A (ja
JP6980659B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/049493 external-priority patent/WO2017040529A1/en
Publication of JP2018526028A publication Critical patent/JP2018526028A/ja
Publication of JP2018526028A5 publication Critical patent/JP2018526028A5/ja
Priority to JP2021131289A priority Critical patent/JP2021180676A/ja
Application granted granted Critical
Publication of JP6980659B2 publication Critical patent/JP6980659B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018530657A 2015-08-31 2016-08-30 抗シアリルtnキメラ抗原受容体 Active JP6980659B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021131289A JP2021180676A (ja) 2015-08-31 2021-08-11 抗シアリルtnキメラ抗原受容体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20150122727 2015-08-31
KR10-2015-0122727 2015-08-31
US201662317950P 2016-04-04 2016-04-04
US62/317,950 2016-04-04
PCT/US2016/049493 WO2017040529A1 (en) 2015-08-31 2016-08-30 Anti-sialyl tn chimeric antigen receptors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131289A Division JP2021180676A (ja) 2015-08-31 2021-08-11 抗シアリルtnキメラ抗原受容体

Publications (3)

Publication Number Publication Date
JP2018526028A JP2018526028A (ja) 2018-09-13
JP2018526028A5 true JP2018526028A5 (https=) 2019-10-10
JP6980659B2 JP6980659B2 (ja) 2021-12-15

Family

ID=58189051

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018530657A Active JP6980659B2 (ja) 2015-08-31 2016-08-30 抗シアリルtnキメラ抗原受容体
JP2021131289A Withdrawn JP2021180676A (ja) 2015-08-31 2021-08-11 抗シアリルtnキメラ抗原受容体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021131289A Withdrawn JP2021180676A (ja) 2015-08-31 2021-08-11 抗シアリルtnキメラ抗原受容体

Country Status (9)

Country Link
US (1) US11279769B2 (https=)
EP (2) EP3344295B1 (https=)
JP (2) JP6980659B2 (https=)
KR (1) KR102715016B1 (https=)
CN (1) CN108136014A (https=)
AU (1) AU2016315704B2 (https=)
CA (1) CA2996893A1 (https=)
ES (1) ES2911015T3 (https=)
WO (1) WO2017040529A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109554350B (zh) 2012-11-27 2022-09-23 儿童医疗中心有限公司 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件
MX375592B (es) 2014-04-25 2025-03-06 The Children´S Medical Center Corp Composiciones y su uso para tratar hemoglobinopatias.
US11572543B2 (en) 2015-05-08 2023-02-07 The Children's Medical Center. Corporation Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction
WO2017040529A1 (en) 2015-08-31 2017-03-09 Bluebird Bio, Inc. Anti-sialyl tn chimeric antigen receptors
US11261441B2 (en) 2017-03-29 2022-03-01 Bluebird Bio, Inc. Vectors and compositions for treating hemoglobinopathies
JP7228523B2 (ja) * 2017-03-29 2023-02-24 ブルーバード バイオ, インコーポレイテッド ヘモグロビン異常症を治療するためのベクターおよび組成物
AU2018265261B2 (en) * 2017-05-10 2025-05-22 Inovio Pharmaceuticals, Inc. Optimized nucleic acid antibody constructs
US11788087B2 (en) 2017-05-25 2023-10-17 The Children's Medical Center Corporation BCL11A guide delivery
TWI731268B (zh) * 2017-09-29 2021-06-21 財團法人國家衛生研究院 可增強抗腫瘤與抗病毒t細胞存活與其功能性之方法與組合物
WO2019101998A1 (en) * 2017-11-24 2019-05-31 Onkimmune Limited Modified natural killer cells and natural killer cell lines targetting tumour cells
PT110526B (pt) * 2018-01-26 2021-02-04 Univ Nova De Lisboa Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
WO2019213273A1 (en) 2018-05-01 2019-11-07 The Children's Medical Center Corporation Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9
WO2019213013A1 (en) 2018-05-02 2019-11-07 The Children's Medical Center Corporation Improved bcl11a micrornas for treating hemoglobinopathies
EP3830133A1 (en) 2018-08-01 2021-06-09 City of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
KR102835308B1 (ko) 2018-08-08 2025-07-21 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
WO2022224242A1 (en) * 2021-04-20 2022-10-27 Ramot At Tel-Aviv University Ltd. Humanized anti-sialyl-tn glycan antibodies and uses thereof
WO2022224241A1 (en) * 2021-04-20 2022-10-27 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptors to sialyl-tn glycan antigen
WO2022246066A2 (en) * 2021-05-19 2022-11-24 Precision Biologics, Inc. Methods and compositions for treating hematological malignancies
EP4511397A1 (en) 2022-04-19 2025-02-26 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
WO2025237313A1 (en) * 2024-05-14 2025-11-20 LaNova Medicines Limited Anti-stn antibodies and conjugates thereof
WO2026057354A1 (en) * 2024-09-10 2026-03-19 Invox Pharma Limited Anti-sialyl-tn antigen-binding proteins

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6962810B2 (en) 2000-10-31 2005-11-08 University Of Notre Dame Du Lac Methods and compositions for transposition using minimal segments of the eukaryotic transformation vector piggyBac
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
US20110047635A1 (en) 2006-08-28 2011-02-24 University of Hawail Methods and compositions for transposon-mediated transgenesis
AU2007304590A1 (en) 2006-10-04 2008-04-10 Cancer Research Technology Limited Generation of a cancer-specific immune response toward MUC1 and cancer specific MUC1 antibodies
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103946952A (zh) * 2011-09-16 2014-07-23 宾夕法尼亚大学董事会 用于治疗癌症的rna改造的t细胞
BR122020002986A8 (pt) * 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US20160264684A1 (en) 2013-10-10 2016-09-15 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN113307880B (zh) 2014-01-13 2025-07-04 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
WO2017040529A1 (en) 2015-08-31 2017-03-09 Bluebird Bio, Inc. Anti-sialyl tn chimeric antigen receptors

Similar Documents

Publication Publication Date Title
JP2018526028A5 (https=)
JP2017538710A5 (https=)
JP2017522882A5 (https=)
JP2021527409A5 (https=)
JP2023539591A5 (https=)
Zhukovsky et al. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
RU2017106025A (ru) Химерные антигенные рецепторы к bcma
JP2021087455A5 (https=)
JP2020517295A5 (https=)
JP2022523961A5 (https=)
JP2020525536A5 (https=)
JP2022537159A5 (https=)
JP2018064568A (ja) Pd−l1によって誘導される免疫寛容の低減
JP2020513754A5 (https=)
JP2019518425A5 (https=)
JP2024023228A5 (https=)
JP2017524367A5 (https=)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
JP2021505137A5 (https=)
CN115386010A (zh) 靶向gprc5d的嵌合抗原受体及其用途
JP2022527081A5 (https=)
JP2021532742A5 (https=)
JP2025081512A5 (https=)
US20240123068A1 (en) Cd19 binders, car-t constructs comprising the same, and methods of using the same
JP2021513857A5 (https=)